HYPOMETHYLATING AGENTS IN TREATMENT OF MYELODYSPLASTIC SYNDROME

Olha Boyko

Abstract


Thelkey to the successful treatment of myelodysplastic syndrome is the careful characterization and diagnosis of the disease, which includes clinical, cytogenetic, biological and molecular investigation of individual patients. Today therapeutic approaches to the treatment of such patients are differentiated and depend, first of all, on the subtype of the disease, age, general condition of the patients and the possibility of allogeneic hematopoietic cell transplantation. For young patients, the best option is transplantation, whereas in older patients, the standard of therapy is the use of hypomethylating agents (azacitidine, decitabine). These drugs promote hematologic improvement, elimination of transfusion dependence and prolongation of the duration of both general and leukemia free survival in elderly patients with concomitant pathology.

Despite the fact that therapy with hypomethylating drugs is widely used and has good results, many respondents are losing their response within 1–2 years. Reasons for the development of resistance to this type of treatment are still unclear, and the insensitivity to drugs is associated with very poor prognosis in patients with all subtypes of myelodysplastic syndrome. Such data and the presence of numerous genetic and epigenetic mechanisms for the development of this pathology have prompted the use of combinations of drugs with different application points and are relevant in terms of research. In the literature review, the results of clinical studies on the use of hypomethylating agents in patients with MDS of low and high risk, as in monotherapy and combined schemes are presented.

The nearest prospect of treatment of myelodysplastic syndrome is the creation of new treatment regimens based on a combination of drugs of different pathogenetic direction for the elimination of the dysplastic clone in order to achieve not only long-term remissions, but also lengthening the duration of overall survival, especially for patients with high risk myelodysplastic syndrome.


Keywords


myelodysplastic syndrome; decitabine; azacitidine; overall survival; leukemia free survival; acute leukemia

Full Text:

PDF

References


Cogle, C. R., Reddy, S. R., Chang, E., Papoyan, E., Broder, M. S., McGuire, M., Binder, G. (2017). Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence. Leukemia Research, 60, 123–128. doi: 10.1016/j.leukres.2017.07.008

Malcovati, L. (2007). Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leukemia Research, 31, 2–6. doi: 10.1016/s0145-2126(07)70459-9

Angelucci, E., Urru, S. A. M., Pilo, F., Piperno, A. (2017). Myelodysplastic Syndromes And Iron Chelation Therapy. Mediterranean Journal of Hematology and Infectious Diseases, 9 (1), e2017021. doi: 10.4084/mjhid.2017.021

Fenaux, P., Ades, L. (2013). How we treat lower-risk myelodysplastic syndromes. Blood, 121 (21), 4280–4286. doi: 10.1182/blood-2013-02-453068

Malcovati, L., Hellstrom-Lindberg, E., Bowen, D., Ades, L., Cermak, J., del Canizo, C. et. al. (2013). Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 122 (17), 2943–2964. doi: 10.1182/blood-2013-03-492884

Sekeres, M. A., Cutler, C. (2013). How we treat higher-risk myelodysplastic syndromes. Blood, 123 (6), 829–836. doi: 10.1182/blood-2013-08-496935

Visconte, V., Selleri, C., Maciejewski, J. P., Tiu, R. V. (2014). Molecular Pathogenesis of Myelodysplastic Syndromes. Translational Medicine UniSa, 8 (4), 19–30.

Kulasekararaj, A. G., Jiang, J., Smith, A. E., Mohamedali, A. M., Mian, S., Gandhi, S. et. al. (2014). Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. Blood, 124 (17), 2698–2704. doi: 10.1182/blood-2014-05-574889

Harada, H., Harada, Y. (2015). Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies. Cancer Science, 106 (4), 329–336. doi: 10.1111/cas.12614

Duchmann, M., Itzykson, R. (2017). Choosing a hypomethylating agent in MDS: does gender matter? Leukemia & Lymphoma, 58 (6), 1277–1278. doi: 10.1080/10428194.2017.1283035

Greenberg, P. L., Stone, R. M., Al-Kali, A., Barta, S. K., Bejar, R., Bennett, J. M. et al. (2017). Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15 (1), 60–87. doi: 10.6004/jnccn.2017.0007

Mies, A., Platzbecker, U. (2017). Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors. Seminars in Hematology, 54 (3), 141–146. doi: 10.1053/j.seminhematol.2017.06.004

Schanz, J., Braulke, F., Mufti,G. J., Crisa, E., Kulasekararaj, A., Nachtkamp, K. et. al. (2014). Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R. Blood, 124 (21), 4656.

Apuri, S., Al Ali, N., Padron, E., Lancet, J. E., List, A. F., Komrokji, R. S. (2017). Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia, 17 (4), 211–214. doi: 10.1016/j.clml.2016.10.003

Madanat, Y., Sekeres, M. A. (2017). Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity. Seminars in Hematology, 54 (3), 147–153. doi: 10.1053/j.seminhematol.2017.06.001

Timothy, A., Razavi, G. E. (2016). Targeted Therapy in Myelodysplastic Syndrome. ECronicon Cancer, 2.1, 34–44.

Tessoulin, B., Delaunay, J., Chevallier, P., Loirat, M., Ayari, S., Peterlin, P. et. al. (2014). Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. Bone Marrow Transplantation, 49 (4), 567–571. doi: 10.1038/bmt.2013.233

Craddock, C., Labopin, M., Robin, M., Finke, J., Chevallier, P., Yakoub-Agha, I. et. al. (2016). Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 101 (7), 879–883. doi: 10.3324/haematol.2015.140996

De Lima, M., Giralt, S., Thall, P. F., de Padua Silva, L., Jones, R. B., Komanduri, K. et. al. (2010). Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 116 (23), 5420–5431. doi: 10.1002/cncr.25500

Antar, A., Kharfan-Dabaja, M. A., Ghaddara, H. A., Mahfouz, R., Bazarbach, A. (2014). Azacitidine Maintenance after Allogeneic Stem Cell Transplantation Is Feasible in Patients with Acute Myeloid Leukemia and Myelodysplasia. Blood, 124 (21), 5884.

Lubbert, M., Suciu, S., Baila, L., Rüter, B. H., Platzbecker, U., Giagounidis, A. et. al. (2011). Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. Journal of Clinical Oncology, 29 (15), 1987–1996. doi: 10.1200/jco.2010.30.9245

Gore, S. D., Fenaux, P., Santini, V., Bennett, J. M., Silverman, L. R., Seymour, J. F. et al. (2013). A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica, 98 (7), 1067–1072. doi: 10.3324/haematol.2012.074831

Musto, P., Maurillo, L., Spagnoli, A., Gozzini, A., Rivellini, F. et. al. (2010). Azacitidine for the treatment of lower risk myelodysplastic syndromes. Cancer, 116 (6), 1485–1494. doi: 10.1002/cncr.24894

Garcia-Delgado, R., de Miguel, D., Bailen, A., Gonzalez, J. R., Bargay, J., Falantes, J. F. et. al. (2014). Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leukemia Research, 38 (7), 744–750. doi: 10.1016/j.leukres.2014.03.004

Cogle, C. R., Scott, B. L., Boyd, T., Garcia-Manero, G. (2015). Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. The Oncologist, 20 (12), 1404–1412. doi: 10.1634/theoncologist.2015-0165

The efficacy and safety of oral azacitidine plus best supportive care versus placebo and best supportive care in subjects with red blood cell (RBC) transfusion-dependent anemia and thrombocytopenia due to International Prognostic Scoring System (IPSS) low risk myelodysplastic syndrome(MDS) (2012). ClinicalTrials. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01566695 Last accessed: 12.01.2015

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes (2013). ClinicalTrials. Available at: https://clinicaltrials.gov/ct2/show/NCT01835587

Santini, V. (2012). Novel therapeutic strategies: hypomethylating agents and beyond. Hematology. American Society of Hematology. Education Program, 2012 (1), 65–73. doi: 10.1182/asheducation-2012.1.65

Killick, S. B., Carter, C., Culligan, D., Dalley, C., Das-Gupta, E. et. al. (2013). Guidelines for the diagnosis and management of adult myelodysplastic syndromes. British Journal of Haematology, 164 (4), 503–525. doi: 10.1111/bjh.12694

Wu, D., Du, X., Jin, J., Xiao, Z., Shen, Z., Shao, Z. et. al. (2015). Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study. Advances in Therapy, 32 (11), 1140–1159. doi: 10.1007/s12325-015-0263-8

Lee, Y.-G., Kim, I., Yoon, S.-S., Park, S., Cheong, J. W. et. al. (2013). Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology, 161 (3), 339–347. doi: 10.1111/bjh.12256

Jabbour, E., Short, N. J., Montalban-Bravo, G., Huang, X., Bueso-Ramos, C., Qiao, W. et. al. (2017). Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood, 130 (13), 1514–1522. doi: 10.1182/blood-2017-06-788497

DeZern, A. E., Zeidan, A. M., Barnard, J., Hand, W., Al Ali, N., Brown, F. et. al. (2016). Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leukemia & Lymphoma, 58 (6), 1325–1331. doi: 10.1080/10428194.2016.1246726

Traina, F., Visconte, V., Elson, P., Tabarroki, A., Jankowska, A. M., Hasrouni, E. et. al. (2013). Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia, 28 (1), 78–87. doi: 10.1038/leu.2013.269

Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Perez-Ladaga, A., Zaneveld, J. et. al. (2014). TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 124 (17), 2705–2712. doi: 10.1182/blood-2014-06-582809

Komrokji, R. S., Sekeres, M. A., Barnard, J., Barnard, J., Alali, N., DeZern, A. E. et. al. (2016). Optimal treatment order of lenalidomide and hypomethylating agents for lower-risk myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Blood, 128 (22), 4322.

Prebet, T., Thepot, S., Gore, S. D., Dreyfus, F., Fenaux, P., Vey, N. (2012). Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica, 98 (2), 18–19. doi: 10.3324/haematol.2012.071050

Garsia-Manero, G., Sekeres, M. A., Edyed, M., Alimena, G., Graux, C., Cavenagh, J. D. et. al. (2015). Panobinostat plus azacitidine in adult patients with MDS, CMML or AML: results of a phase 2b study. Blood, 126 (3), 2861.

Zeidan, A. M., Kharfan-Dabaja, M. A., Komrokji, R. S. (2014). Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion in Hematology, 21 (2), 123–130. doi: 10.1097/moh.0000000000000016

Duong, V. H., Lin, K., Reljic, T., Kumar, A., Al Ali, N. H., Lancet, J. E. et. al. (2013). Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure. Clinical Lymphoma Myeloma and Leukemia, 13 (6), 711–715. doi: 10.1016/j.clml.2013.07.007

Prebet, T., Gore, S. D., Thepot, S., Esterni, B., Quesnel, B., Beyne Rauzy, O. et. al (2012). Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. British Journal of Haematology, 157 (6), 764–766. doi: 10.1111/j.1365-2141.2012.09076.x




DOI: http://dx.doi.org/10.21303/2504-5679.2018.00626

Refbacks

  • There are currently no refbacks.




Copyright (c) 2018 Olha Boyko

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)